Soligenix (SNGX) News Today $2.43 -0.01 (-0.41%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.44 +0.01 (+0.62%) As of 02/21/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period EQS-News: Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026February 21 at 5:13 PM | markets.businessinsider.comSoligenix IncFebruary 18, 2025 | money.usnews.comSoligenix settles debt with Pontifax lendersFebruary 10, 2025 | msn.comSoligenix Repays Loan, Boosting Financial FlexibilityFebruary 10, 2025 | tipranks.comSoligenix on Way to Bio Conference in NYCFebruary 4, 2025 | baystreet.caSoligenix to Present at BIO CEO & Investor ConferenceFebruary 4, 2025 | prnewswire.comSoligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical NeedsJanuary 23, 2025 | msn.comSoligenix to Present at Upcoming Investor ConferencesJanuary 16, 2025 | prnewswire.comSNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…January 14, 2025 | msn.comHyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJanuary 14, 2025 | prnewswire.comSoligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trialDecember 19, 2024 | msn.comSNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…December 17, 2024 | msn.comSoligenix initiates confirmatory Phase 3 trial of HyBryteDecember 17, 2024 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaDecember 16, 2024 | finanznachrichten.deSoligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaDecember 16, 2024 | prnewswire.comSoligenix announces analysis from protocol HPN-CTCL-04December 3, 2024 | markets.businessinsider.comHyBryte™ Clinical Results Demonstrate Continued Improvement Post-TreatmentDecember 2, 2024 | prnewswire.comSoligenix forms European Medical Advisory BoardNovember 20, 2024 | markets.businessinsider.comSoligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNovember 19, 2024 | prnewswire.comSoligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s DiseaseNovember 15, 2024 | markets.businessinsider.comSOLIGENIX, INC.: Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNovember 14, 2024 | finanznachrichten.deSoligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNovember 14, 2024 | prnewswire.comSNGX: Phase 3 CTCL Trial to Initiate Before End of 2024November 12, 2024 | finance.yahoo.comSoligenix Announces Recent Accomplishments And Third Quarter 2024 Financial ResultsNovember 8, 2024 | prnewswire.comSoligenix gains Hong Kong patent for synthetic hypericinOctober 25, 2024 | investing.comSoligenix, Inc. to Present at the 2024 ThinkEquity ConferenceOctober 24, 2024 | globenewswire.comSoligenix granted Hong Kong patent for production of synthetic hypericinOctober 23, 2024 | markets.businessinsider.comSoligenix Receives Hong Kong Patent for Improved Production of Synthetic HypericinOctober 22, 2024 | prnewswire.comSoligenix Invited to Present at Upcoming Investor ConferencesOctober 16, 2024 | prnewswire.comHyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOctober 7, 2024 | prnewswire.comSNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development…October 3, 2024 | msn.comSoligenix (NASDAQ:SNGX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comSoligenix, Sterling Pharma Partner To Develop Production Technology For Synthetic HypericinOctober 3, 2024 | markets.businessinsider.comSoligenix Announces Partnership with Sterling Pharma SolutionsOctober 3, 2024 | prnewswire.comJoin Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024September 16, 2024 | prnewswire.comSoligenix Receives European Patent for Improved Production of Synthetic HypericinSeptember 3, 2024 | prnewswire.comSNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24…August 13, 2024 | finance.yahoo.comSoligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 13, 2024 | uk.finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsAugust 9, 2024 | finanznachrichten.deSoligenix Trumpets Q2 NumbersAugust 9, 2024 | baystreet.caSoligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsAugust 9, 2024 | prnewswire.comStrong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian PoligoneAugust 1, 2024 | finance.yahoo.comMarketBeat Week in Review – 7/8 - 7/12 (SNGX)Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the weekJuly 13, 2024 | marketbeat.comUncover Why This Pharma Stock Jumped 400% on Study UpdateSoligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%.July 10, 2024 | marketbeat.comUncover Why This Pharma Stock Jumped 400% on Study UpdateShares of Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, surged almost 400% today after announcing positive data.July 10, 2024 | marketbeat.com5 Investors Betting Big on Soligenix (SNGX) StockJuly 9, 2024 | investorplace.comWhy Is Soligenix (SNGX) Stock Up 296% Today?July 9, 2024 | investorplace.comExpanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJuly 9, 2024 | prnewswire.comSoligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell LymphomaJune 25, 2024 | prnewswire.comA Comparison of Vaccine Technologies to be Presented at the ASM Microbe ConferenceJune 14, 2024 | prnewswire.com Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Media Mentions By Week SNGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNGX News Sentiment▼0.240.60▲Average Medical News Sentiment SNGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNGX Articles This Week▼21▲SNGX Articles Average Week Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DURECT News Today Cara Therapeutics News Today Citius Pharmaceuticals News Today Traws Pharma News Today Enlivex Therapeutics News Today BioAtla News Today Tonix Pharmaceuticals News Today Lakeshore Biopharma News Today Mannatech News Today 60 Degrees Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNGX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
